1-[3-(4-硝基苯氧基)丙基]哌啶 | 92374-75-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-[3-(4-硝基苯氧基)丙基]哌啶
• 英文名称: 1-[3-(4-nitro-phenoxy)-propyl]-piperidine
• 英文别名: 1-[3-(4-Nitrophenoxy)propyl]piperidine
• CAS: 92374-75-9
• 化学式: C₁₄H₂₀N₂O₃
• 分子量: 264.324
• InChiKey: JEVKRDOAGIIPGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  58.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-[3-(4-硝基苯氧基)丙基]哌啶 在 palladium 10% on activated carbon 、 氢气 、 sodium acetate 作用下， 以 甲醇 、 乙醇 、 水 、 溶剂黄146 为溶剂， 生成 C₃₁H₃₁N₃O₄S₂
  参考文献：
  名称：

  Discovery of potent and selective rhodanine type IKKβ inhibitors by hit-to-lead strategy

  摘要：

  Regulation of NF-kappa B activation through the inhibition of IKK beta has been identified as a promising target for the treatment of inflammatory and autoimmune disease such as rheumatoid arthritis. In order to develop novel IKK beta inhibitors, we performed high throughput screening toward around 8000 library compounds, and identified a hit compound containing rhodanine moiety. We modified the structure of hit compound to obtain potent and selective IKK beta inhibitors. Throughout hit-to-lead studies, we have discovered optimized compounds which possess blocking effect toward NF-kappa B activation and TNF alpha production in cell as well as inhibition activity against IKK beta. Among them, compound 3q showed the potent inhibitory activity against IKK beta, and excellent selectivity over other kinases such as p38 alpha, p38 beta, JNK1, JNK2, and JNK3 as well as IKK alpha. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.088
• 作为产物：
  描述：

  哌啶 在 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-[3-(4-硝基苯氧基)丙基]哌啶
  参考文献：
  名称：

  Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors

  摘要：

  The insulin-like growth factor-1 receptor (IGF-1R) plays an important role in the regulation of cell growth and differentiation, and in protection from apoptosis. IGF-1R has been shown to be an appealing target for the treatment of human cancer. Herein, we report the synthesis, structure-activity relationships (SAR), X-ray cocrystal structure and in vivo tumor study results for a series of 2,4-bis-arylamino-1,3-pyrimidines. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.075

文献信息

• Imidazole and benzimidazole derivatives useful as histamine H3 antagonists
  申请人：Aslanian G. Robert

  公开号：US20060166960A1

  公开（公告）日：2006-07-27

  Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein: n is 2-5; R is R 3 -aryl, R 3 -heteroaryl, R 3 -cycloalkyl, R 3 -heterocycloalkyl, alkyl, haloalkyl, —OR 4 , —SR 4 or —S(O) 1-2 R 5 ; R 1 and R 2 are H or optionally substituted phenyl or optionally substituted and X is —O— or —S—; or R 1 and R 2 , together with the carbon atoms to which they are attached form optionally substituted and X is —O—, —S— or —NR 7 —; Z is and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I; also disclosed are methods of treating allergy, allergy-induced airway responses, congestion, obesity and metabolic syndrome using the compounds of Formula I, as well as combinations with other drugs useful for treating those diseases.

  揭示了以下公式化合物或其药学上可接受的盐或溶剂，其中：n为2-5；R为R3-芳基，R3-杂环芳基，R3-环烷基，R3-杂环烷基，烷基，卤代烷基，—OR4，—SR4或—S(O)1-2R5；R1和R2为H或可选择地取代的苯基或可选择地取代的，X为—O—或—S—；或R1和R2，连同它们连接的碳原子形成可选择地取代的，X为—O—，—S—或—NR7—；Z为，其余变量如规范中所定义；还揭示了包括公式I化合物的药物组合物；还揭示了使用公式I化合物治疗过敏、过敏引起的气道反应、充血、肥胖和代谢综合征的方法，以及与其他用于治疗这些疾病的药物的组合。
• Aryl nitrogen-containing bicyclic compounds and methods of use
  申请人：Patel F. Vinod

  公开号：US20070054916A1

  公开（公告）日：2007-03-08

  The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A 1 , A 2 , A 3 , B, R 1 , R 2 , R 3 and R 4 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.

  这项发明涉及一类新的化合物，用于预防和治疗蛋白激酶介导的疾病，包括炎症、癌症和相关疾病。这些化合物具有一般的化学式I，其中A1、A2、A3、B、R1、R2、R3和R4在此有定义。因此，该发明还涉及包括该发明的化合物的药物组合物，使用该发明的化合物和组合物预防和治疗激酶介导的疾病的方法，以及用于制备该发明的化合物的中间体和方法。
• Fused ring 4-oxopyrimidine derivative
  申请人：Nagase Tsuyoshi

  公开号：US20050182045A1

  公开（公告）日：2005-08-18

  The present invention provides a compound represented by formula (I) below, or a pharmaceutically acceptable salt thereof, which, having histamine H3 receptor antagonist or inverse agonist activity, is useful in the prophylaxis or therapy of metabolic diseases, circulatory diseases, or nervous system diseases. [where, for example, Ar is a divalent group formed by eliminating two hydrogen atoms from benzene, X 1 is a nitrogen atom, sulfur atom or oxygen atom, R 1 is a 5- to 6-membered heteroaryl group, Ring A is a 5- to 6-membered heteroaryl ring, R 2 and R 3 are amino groups or alkylamino groups, and X 2 is represented by formula (II): (where R 4 and R 5 are lower alkyl groups, and n is an integer from 2 to 4).]

  本发明提供以下公式（I）所表示的化合物或其药学上可接受的盐，具有组织胺H3受体拮抗剂或逆激动剂活性，在代谢性疾病、循环系统疾病或神经系统疾病的预防或治疗中有用。【其中，例如，Ar是通过从苯中消除两个氢原子形成的二价基团，X1是氮原子、硫原子或氧原子，R1是5-至6-成员杂芳基团，环A是5-至6-成员杂芳基环，R2和R3是氨基或烷基氨基，X2由以下公式（II）表示：（其中R4和R5是较低烷基基团，n是从2到4的整数）。】
• Novel 2-Aminopyrimidine Carbamates as Potent and Orally Active Inhibitors of Lck:  Synthesis, SAR, and in Vivo Antiinflammatory Activity
  作者：Matthew W. Martin、John Newcomb、Joseph J. Nunes、David C. McGowan、David M. Armistead、Christina Boucher、John L. Buchanan、William Buckner、Lilly Chai、Daniel Elbaum、Linda F. Epstein、Theodore Faust、Shaun Flynn、Paul Gallant、Anu Gore、Yan Gu、Faye Hsieh、Xin Huang、Josie H. Lee、Daniela Metz、Scot Middleton、Deanna Mohn、Kurt Morgenstern、Michael J. Morrison、Perry M. Novak、Antonio Oliveira-dos-Santos、David Powers、Paul Rose、Stephen Schneider、Stephanie Sell、Yanyan Tudor、Susan M. Turci、Andrew A. Welcher、Ryan D. White、Debra Zack、Huilin Zhao、Li Zhu、Xiaotian Zhu、Chiara Ghiron、Patricia Amouzegh、Monika Ermann、James Jenkins、David Johnston、Spencer Napier、Eoin Power

  DOI：10.1021/jm060435i

  日期：2006.8.1

  humans demonstrates that Lck kinase activity is critical for signaling mediated by the T cell receptor (TCR), which leads to normal T cell development and activation. A small molecule inhibitor of Lck is expected to be useful in the treatment of T cell-mediated autoimmune and inflammatory disorders and/or organ transplant rejection. In this paper, we describe the synthesis, structure-activity relationships

  淋巴细胞特异性激酶（Lck）是在T细胞和NK细胞中表达的Src家族的胞质酪氨酸激酶。小鼠和人类的遗传证据均表明，Lck激酶活性对于由T细胞受体（TCR）介导的信号至关重要，后者可导致正常的T细胞发育和激活。预期Lck的小分子抑制剂可用于治疗T细胞介导的自身免疫和炎性疾病和/或器官移植排斥。在本文中，我们描述了2-氨基嘧啶氨基甲酸酯的合成，结构-活性关系以及药理学表征，这是一类对Lck具有有效和选择性抑制作用的新型化合物。该系列中最有希望的化合物2,6-二甲基苯基2-（（3，
• Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer’s disease
  作者：Zonghua Luo、Liang Liang、Jianfei Sheng、Yanqing Pang、Jianheng Li、Ling Huang、Xingshu Li

  DOI：10.1016/j.bmc.2013.12.066

  日期：2014.2

  A series of ebselen derivatives were designed, synthesised and evaluated as inhibitors of cholinesterases (ChEs) and glutathione peroxidase (GPx) mimics. Most of the compounds were found to be potent against AChEs and BuChE, compounds 5e and 5i, proved to be the most potent against AChE with IC50 values of 0.76 and 0.46 μM, respectively. Among these hybrids, most of the compounds were found to be good

  设计，合成和评估了一系列依布硒仑衍生物，作为胆碱酯酶（ChEs）和谷胱甘肽过氧化物酶（GPx）模拟物的抑制剂。发现大多数化合物对AChE和BuChE均有效，化合物5e和5i被证明对AChE最有效，IC 50值分别为0.76和0.46μM。在这些杂种中，与ebselen相比，发现大多数化合物都是良好的GPx模拟物。所选择的化合物5e和5i还用于确定催化参数和体外过氧化氢清除活性。结果表明化合物5e和5i 可能是治疗AD的优秀多功能药物。